Table 4: Treatment
and follow-up.
|
Characteristics |
FMF |
|
|
|
Median
follow-up in years(range) |
9.5
(1-34) |
|
|
|
Initial
treatment |
PUVA |
5 |
|
|
|
BCNU |
2 |
|
|
|
PUVA+BCNU |
1 |
|
|
|
Chemotherapy
(CHVmP-BV) |
1 |
|
|
|
Isotretinoin |
1 |
|
|
Complete
remission on initial treatment |
2 |
2/8 |
|
|
Current
status |
ASD |
5 |
|
|
|
NED |
1 |
|
|
|
APD |
1 |
|
|
|
DOL |
3 |
|
ASD
= Alive with stable disease; NED = No evidence of disease; APD = Alive with
progressive disease; DOL = Died of lymphoma progression; PUVA = Psoralen + UVA; BCNU = Chlormustine
or bis-chloronitrosourea; CHVmP-BV
= Cyclophosphamide, doxorubicin, teniposide and
prednisone with bleomycin and vincristine